ADCYAP1R1 Specific Neutra™ Antibody Products

ADCYAP Receptor Type I is a gene that encodes adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1), also known as PAC1R. This receptor is specific for PACAP-27 and PACAP-38. ADCYAP1R1 protein has a molecular weight of 57 kD and is mainly distributed in the central nervous system, with low expression in the lungs, thymus, and spleen. ADCYAP1R1 activates adenylate cyclase via G proteins to initiate relevant downstream signaling pathways. It is involved in the regulation of several hormone releases, including adrenocorticotropic hormone, epinephrine, luteinizing hormone, growth hormone, prolactin, and catecholamines. ADCYAP1R1 has been demonstrated to play a crucial role in the central and peripheral nervous system.

Its Gene ID: 117, UniProtKB ID: P41586, and OMIM ID: 102981.

PACAP/ADCYAP1R1 Signaling

PACAP is a neuropeptide that functions as a neurotransmitter and neuromodulator in the nervous system. The signaling pathway of PACAP through its receptor ADCYAP1R1 is integral to various cascades such as adenylyl cyclase/cAMP, phospholipase C/Diacylglycerol/Protein Kinase C, MEK/ERK, and PI3K/Akt, all of which are closely associated with neuronal functions. In cases of chronic or repeated injury, the ADCYAP1R1-mediated signaling pathways can trigger chronic pain and stress-related disorders. Conversely, ADCYAP1R1 is also known to facilitate neurotrophic signaling, which helps in mitigating neurodegenerative disorders and maintaining energy balance in metabolic regulation, particularly in addressing issues related to obesity and diabetes mellitus.

Fig.1 PACAP/ADCYAP1R1 signaling to ERK activation.¹

PACAP/ADCYAP1R1 Signaling in Migraine

Recent studies have highlighted the role of PACAP/ADCYAP1R1 signaling in the pathophysiology of migraine, a prevalent chronic neurovascular condition. Migraine is closely associated with two neuropeptides, calcitonin gene-related peptide (CGRP) and PACAP, with CGRP being the focus of recent antibody-based treatments. Despite the success of CGRP receptor blockade in alleviating migraine symptoms, a significant portion of patients (40%) do not experience substantial relief with these medications. PACAP, similar to CGRP, has been found to induce dilation of intracranial arteries, leading to migraine symptoms upon administration. Notably, PACAP shows promise for antibody-based therapy, making it a viable target for migraine treatment. Presently, various anti-PACAP/ADCYAP1R1 monoclonal antibodies are undergoing clinical trials for migraine management. This development suggests that targeting PACAP/ADCYAP1R1 signaling could offer a new avenue for effectively managing migraines, particularly for patients who have not responded well to CGRP antibody therapies.

Creative Biolabs offers a wide range of anti-ADCYAP1R1 neutralizing antibodies to support research in neuroscience and signaling pathways. Our antibody products are rigorously tested to ensure high specificity and sensitivity, making them ideal for multiple applications including ELISA, Neutralization and function assays.

REFERENCE

1. Tanaka, Masaru, et al. "From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment." Cells 12.22 (2023): 2649. Distributed under open access license CC BY 4.0, without modification.